论文部分内容阅读
目的探讨同步放化疗治疗局部晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法局部晚期NSCLC患者31例,实施胸部三维适形放射治疗,2Gy/次、5次/周、计划照射剂量60～70Gy/6～7周。同步行GP方案化疗,方案为:吉西他滨1000 mg/m2,第1、8天,顺铂75mg/m2,第1、2、3天。3周1次,共2个周期,放疗结束后继续完成2～4个周期化疗。结果总有效率77.42%(24/31),1.2a生存率分别为77.49%、32.35%。中位生存期16.1个月。结论对局部晚期NSCLC采用同步放化疗有较好的疗效,不良反应可耐受。
Objective To investigate the efficacy and adverse reactions of concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer (NSCLC). Methods Totally 31 patients with locally advanced NSCLC underwent 3-D conformal radiotherapy of the thorax, 2Gy / time, 5 times / week, and the dose of irradiation was 60-70Gy / 6-7 weeks. The concurrent chemotherapy with GP regimen, the program is: gemcitabine 1000 mg / m2, the first 1,8 days, cisplatin 75mg / m2, days 1,2,3. 3 times a week, a total of 2 cycles, after radiotherapy to continue to complete 2 to 4 cycles of chemotherapy. Results The total effective rate was 77.42% (24/31), 1.2a survival rates were 77.49%, 32.35%. The median survival time was 16.1 months. Conclusion Concurrent chemoradiotherapy with locally advanced NSCLC has better curative effect and adverse reactions can be tolerated.